Clinical Trial

The Clinical Efficacy of Immunomodulators in RA Patients

Recruiting Phase 4
View on ClinicalTrials.gov →
Record status
This record was last updated November 29, 2022 (before its estimated June 30, 2025 completion). Its status may not reflect the trial's current state.
Summary
This study includes naive patients and csDMARDs-IR RA patients, treated with different regimens such as Iguratimod combination of different csDMARDs, or csDMARD with TNF inhibitors for 24 weeks. The disease activity and drug response will be observed. The immune disorder and synovial function will be evaluated at the same time.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2022-11-15.
Trial Details
NCT Number NCT05626348
Lead Sponsor Qilu Hospital of Shandong University
Conditions Arthritis, Rheumatoid
Enrollment 400 participants
Start Date 2021-12-22
Primary Completion 2025-06-30 (estimated)
Study Completion 2026-12-31 (estimated)
Updated on ClinicalTrials.gov 2022-11-29